Goldman Sachs analyst Paul Choi suspended the firm’s investment rating, price target and earnings estimates for Gossamer Bio (GOSS). Given the “going concern” warning within its financials and uncertainty of obtaining additional capital to fund operations, there is currently not sufficient basis for determining an investment rating, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio Balances Seralutinib Promise With Cash Strain
- Gossamer Bio price target lowered to 28c from 30c at Barclays
- Midday Fly By: Dominion to combine with NextEra, Publicis to acquire LiveRamp
- Morning Movers: LiveRamp jumps following pact to be acquired by Publicis
- Gossamer Bio Restructures Debt and Advances Seralutinib Program